Evogene
EVGN
21 hedge funds and large institutions have $20.8M invested in Evogene in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
15% more capital invested
Capital invested by funds: $18.2M → $20.8M (+$2.65M)
1.7% less ownership
Funds ownership: 35.4% → 33.7% (-1.7%)
9% less funds holding
Funds holding: 23 → 21 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$846K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$188K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$73.2K |
| 4 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$18.6K |
| 5 |
DG
Delek Group
Herzliya,
Israel
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.08M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$833K |
| 3 |
Morgan Stanley
New York
|
-$69.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$28K |
| 5 |
SWM
Stockman Wealth Management
Billings,
Montana
|
-$25K |
EVGN Hedge Fund Activity: Q1 2019 in Review
21 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q1 2019, worth a combined $20.8M — up 15% from $18.2M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EVGN and 1 opened new positions — a net loss of 2 holders — while 5 trimmed existing stakes and 7 added.
The largest buyer was Goldman Sachs, adding an estimated $846K. The largest seller was Vanguard Group, cutting an estimated $1.08M.
- 21 institutional investors held Evogene (EVGN) as of Q1 2019, down from 23 in Q4 2018.
- Funds reported $20.8M of Evogene stock for Q1 2019, up 15% quarter-over-quarter.
- 1 fund opened new Evogene positions in Q1 2019 and 3 closed out, a net change of -2 holders.
- The largest Evogene buyer in Q1 2019 was Goldman Sachs, an estimated $846K added.
- The largest Evogene seller in Q1 2019 was Vanguard Group, an estimated $1.08M sold.
Based on aggregated 13F filings for Q1 2019.